CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 39 enrolled
Drug / intervention
Ipratropium Bromidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04617015
NCT04617015Early Ph 1Completed
CompareCT.gov

Defining and Treating a New Pediatric Asthma Endotype: Depression-related Asthma Mediated by the Cholinergic Pathway

State University of New York at Buffalo·interventional·Posted Nov 5, 2020·Updated Apr 23, 2026

In Brief

A Early Phase 1 clinical trial evaluating Ipratropium Bromide for Asthma and 2 related conditions. Completed, enrolled 39 participants across 1 site.

Detailed Summary

Depression is seen more often in people with asthma, and may lead to increased development and severity of asthma. This study will investigate whether children with depression and asthma have less allergic disease and less inflammation than children with asthma who do not have symptoms of depression. The study will also investigate whether the lungs of children with depression and asthma respond to an anticholinergic inhaler called ipratropium more than the lungs of non-depressed asthmatic children.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma, Depression, Childhood Asthma
CountriesUnited States
CollaboratorsNational Center for Advancing Translational Sciences (NCATS)

Timeline

Early Ph 1CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 5, 2020
Enrollment StartSep 9, 2016
Primary CompletionMar 11, 2019
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 5.7 years ago

Interventions

Ipratropium Bromidedrug

All subjects receive inhaled ipratropium once with measurement of spirometry before and after. Bronchodilator response of subjects with depression is compare to that of subjects without depression.